Teva Pharmaceutical Industries (NYSE:TEVA) Raised to Overweight at JPMorgan Chase & Co.

Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by investment analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday, MarketBeat Ratings reports. The firm presently has a $23.00 price target on the stock, up from their previous price target of $21.00. JPMorgan Chase & Co.‘s price objective points to a potential upside of 31.58% from the stock’s previous close.

A number of other equities analysts have also weighed in on TEVA. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Finally, Bank of America increased their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $24.43.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $17.48 on Monday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock’s 50 day moving average price is $15.22 and its two-hundred day moving average price is $17.44. The firm has a market capitalization of $19.82 billion, a price-to-earnings ratio of -12.06, a P/E/G ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.48 earnings per share. On average, analysts anticipate that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently modified their holdings of TEVA. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $29,000. Golden State Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $39,000. New Age Alpha Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $43,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $44,000. Finally, Compagnie Lombard Odier SCmA acquired a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $54,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.